These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12903576)

  • 1. [Postoperative complications and local recurrence of mid-lower rectal carcinoma treated with neoadjuvant chemoradiotherapy and surgery. Preliminary results].
    Tonin D; Scatà A; Stuto A; Rota G; Doffria E; Tosolini G
    Tumori; 2003; 89(4 Suppl):149-51. PubMed ID: 12903576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Local recurrence and survival rate after rectal cancer operations and multimodal therapy].
    Thomschke D; Kyau-Ummen B; Halbfass HJ
    Chirurg; 2002 Mar; 73(3):245-54. PubMed ID: 11963499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
    Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
    Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphincter-Sparing Surgery in Patients with Mid and Low Rectal Cancer - Risk Factors for Local Recurrence and Anastomotic Leakage.
    Aslan D; Grama F; Cristian D; Bordea A; Burcoş T;
    Chirurgia (Bucur); 2016; 111(6):481-486. PubMed ID: 28044949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morbidity and mortality following abdominoperineal resection for low rectal adenocarcinoma.
    Luna-Pérez P; Rodríguez-Ramírez S; Vega J; Sandoval E; Labastida S
    Rev Invest Clin; 2001; 53(5):388-95. PubMed ID: 11795103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of early postoperative morbidity among patients with rectal cancer treated with and without neoadjuvant chemoradiotherapy.
    Valenti V; Hernandez-Lizoain JL; Baixauli J; Pastor C; Aristu J; Diaz-Gonzalez J; Beunza JJ; Alvarez-Cienfuegos JA
    Ann Surg Oncol; 2007 May; 14(5):1744-51. PubMed ID: 17334851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laparoscopic total mesorectal excision (TME) for rectal cancer surgery: long-term outcomes.
    Leroy J; Jamali F; Forbes L; Smith M; Rubino F; Mutter D; Marescaux J
    Surg Endosc; 2004 Feb; 18(2):281-9. PubMed ID: 14691716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of neoadjuvant short-course radiation therapy followed by transanal endoscopic microsurgery for t1-t2 n0 extraperitoneal rectal cancer.
    Arezzo A; Arolfo S; Allaix ME; Munoz F; Cassoni P; Monagheddu C; Ricardi U; Ciccone G; Morino M
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):299-306. PubMed ID: 25772184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.
    de Campos-Lobato LF; Stocchi L; da Luz Moreira A; Geisler D; Dietz DW; Lavery IC; Fazio VW; Kalady MF
    Ann Surg Oncol; 2011 Jun; 18(6):1590-8. PubMed ID: 21207164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
    Perez RO; Habr-Gama A; Lynn PB; São Julião GP; Bianchi R; Proscurshim I; Gama-Rodrigues J
    Dis Colon Rectum; 2013 Jan; 56(1):6-13. PubMed ID: 23222274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative chemoradiation and coloanal J pouch reconstruction for low rectal cancer.
    Chaudhry V; Nittala M; Prasad ML
    Am Surg; 2000 Apr; 66(4):387-93. PubMed ID: 10776877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
    Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
    Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
    Pacelli F; Sanchez AM; Covino M; Tortorelli AP; Bossola M; Valentini V; Gambacorta MA; Doglietto GB
    Am Surg; 2013 Feb; 79(2):151-61. PubMed ID: 23336654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.
    Landi F; Espín E; Rodrigues V; Vallribera F; Martinez A; Charpy C; Brunetti F; Azoulay D; de'Angelis N
    Int J Colorectal Dis; 2017 Feb; 32(2):255-264. PubMed ID: 27757541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative radiochemotherapy in t3 operable low rectal cancers: a gold standard?
    Fucini C; Pucciani F; Elbetti C; Gattai R; Russo A
    World J Surg; 2010 Jul; 34(7):1609-14. PubMed ID: 20213202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The surgeon as prognostic factor for local recurrence and survival in the anal sphincter preservation for mid-rectal cancer.
    Luna-Pérez P; Reyna Huelga A; Labastida Almendaro S; Rodríguez-Coria DF; González Macouzet J; Delgado Gallardo S
    Rev Invest Clin; 1999; 51(4):205-13. PubMed ID: 10546501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
    Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM
    Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
    Bouzourene H; Bosman FT; Seelentag W; Matter M; Coucke P
    Cancer; 2002 Feb; 94(4):1121-30. PubMed ID: 11920483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.